Annexin Pharmaceuticals AB AI Stock Analysis
Want to see SE:ANNX full AI Analyst Report?
Annexin Pharmaceuticals AB (ANNX) AI Stock Analysis
Annexin Pharmaceuticals AB
(Nasdaq OMX AB:ANNX)
The overall score is heavily pressured by the company's precarious financial position, specifically a cash runway that appears critically short relative to its burn rate, creating an imminent need for dilutive financing. This fundamental risk is the dominant factor. The technical picture offers a minor positive signal with a short-term bounce, but the stock remains in a broader downtrend, and standard valuation metrics are inapplicable due to negative earnings.
Annexin Pharmaceuticals AB (ANNX) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 78.81M
- Dividend Yield
- ―
- Average Volume (3M)
- 9,796
- Price to Earnings (P/E)
- -2.1
- Beta (1Y)
- 0.81
- Revenue Growth
- ―
- EPS Growth
- 7.33%
- Country
- Sweden
- Employees
- 4
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Annexin Pharmaceuticals AB Business Overview & Revenue Model
Company Description
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and...
Annexin Pharmaceuticals AB Financial Statement Overview
Summary
The company is pre-revenue with a critically short cash runway. While it has no debt and annual losses are narrowing, the TTM equity base of SEK 12.3M is insufficient to cover a TTM free cash flow burn of SEK 41.2M, making near-term dilution highly likely.
Income Statement
1Very NegativeBalance Sheet
45NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -48.00K | -48.00K | -193.00K | -193.00K | -193.00K | -192.00K |
| EBITDA | -42.01M | -36.84M | -50.20M | -43.86M | -40.72M | -50.28M |
| Net Income | -42.08M | -36.89M | -50.25M | -44.05M | -40.73M | -52.14M |
Balance Sheet | ||||||
| Total Assets | 17.66M | 30.16M | 19.04M | 26.76M | 36.68M | 52.79M |
| Cash, Cash Equivalents and Short-Term Investments | 14.44M | 27.39M | 16.34M | 21.41M | 31.11M | 49.48M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 5.33M | 5.22M | 5.32M | 7.95M | 6.53M | 6.06M |
| Stockholders Equity | 12.33M | 24.93M | 13.71M | 18.81M | 30.15M | 46.73M |
Cash Flow | ||||||
| Free Cash Flow | -41.22M | -37.05M | -50.23M | -43.40M | -41.16M | -45.02M |
| Operating Cash Flow | -41.22M | -36.92M | -50.23M | -43.40M | -41.16M | -45.02M |
| Investing Cash Flow | -178.00K | -129.00K | 0 | 96.00K | -260.00K | 0 |
| Financing Cash Flow | 18.96M | 48.11M | 45.15M | 33.61M | 23.06M | 76.37M |
Annexin Pharmaceuticals AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ANNX, the sentiment is Negative. The current price of 9.00 is above the 20-day moving average (MA) of 7.86, below the 50-day MA of 9.30, and below the 200-day MA of 12.62, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 57.21 is Neutral, neither overbought nor oversold. The STOCH value of 82.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ANNX.
Annexin Pharmaceuticals AB Peers Comparison
Overall Rating
SE:CANTA61Neutral
SE:XBRANE46Neutral
SE:BINV43Neutral
SE:ANNX42Neutral
SE:SPAGO42Neutral
SE:BIOVIC.B41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | SEK 391.34M | 2.04 | 63.09% | ― | ― | ― | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 46Neutral | SEK 235.93M | -6.34 | -11.52% | ― | -38.80% | -120.18% | |
| 43Neutral | SEK 191.82M | -0.39 | -128.54% | ― | -83.67% | -50.29% | |
| 42Neutral | SEK 78.81M | -2.05 | ― | ― | ― | 7.33% | |
| 42Neutral | SEK 35.93M | -1.13 | -87.37% | ― | -97.52% | 31.31% | |
| 41Neutral | SEK 87.79M | -1.22 | -75.51% | ― | 56.06% | 63.95% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ANNX | Annexin Pharmaceuticals AB | 9.00 | -15.82 | -63.74% | |
| SE:BINV | BioInvent International AB | 2.75 | -26.20 | -90.50% | |
| SE:XBRANE | Xbrane Biopharma AB | 10.65 | 0.70 | 6.98% | |
| SE:BIOVIC.B | Biovica International AB Class B | 0.30 | -0.24 | -44.69% | |
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.07 | -60.00% | |
| SE:CANTA | Cantargia AB | 1.37 | -2.05 | -60.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
